← Eichor
Study identifier: NCT04227314 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis

Condition: Recurrent Aphtous Stomatitis  ·  Sponsor: University Hospital, Rouen

PhasePhase 3
Planned participants134
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The objective of the study is to assess the superiority of apremilast in comparison with placebo to achieve Complete Remission (CR) of oral ulcers at Week 12, in patients with severe Recurrent aphtous stomatitis resistant or intolerant to colchicine.

This description comes directly from the study's public registry record.

Talk to the study team

Pascal JOLY, Pr  ·  +3323288  ·  pascal.joly@chu-rouen.fr

Julien BLOT  ·  +3323288  ·  julien.blot@chu-rouen.fr

Always discuss trial participation with your own doctor first.

Locations (21)

Chu AmiensAmiens, FranceNot Yet Recruiting
Ap-Hp AvicenneBobigny, FranceRecruiting
Chu BordeauxBordeaux, FranceRecruiting
Chru BrestBrest, FranceRecruiting
Ch CreteilCréteil, FranceRecruiting
Ch Le MansLe Mans, FranceRecruiting
Chu LilleLille, FranceRecruiting
Hcl Hopital Edouard HerriotLyon, FranceRecruiting
Ap-Hm La TimoneMarseille, FranceRecruiting
Chu MontpellierMontpellier, FranceRecruiting
Chu NantesNantes, FranceRecruiting
CHU NICENice, FranceRecruiting

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04227314